Covid-19: Sputnik vaccine rockets, thanks to Lancet boost
Christoffer van Tulleken
Abstract
Journals risk being used in place of regulators when they publish studies of novel vaccines that have not yet been authorised by a major regulator. <b>Chris van Tulleken</b> argues that peer review is inadequate to decide the risk-benefit ratio of new drugs
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakPublicationMedicineInternet privacyVirologyComputer sciencePolitical scienceLawOutbreakInfectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsHealthcare Systems and Challenges